Kala Pharmaceuticals

Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

KALA BIO, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

The consensus price target hints at a 143.9% upside potential for Kala Pharma (KALA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Kala Pharma (KALA)? Wall Street Analysts Think 143.91%

Kala's Q4 earnings miss estimates. Its shares rise in pre-market trading on Mar 6.

KALA Q4 Loss Wider Than Expected, Pipeline Remains in Focus

-- Enrolled first patient in CHASE Phase 2b clinical trial evaluating KPI-012 for PCED; Top-line data targeted for 1Q 2024 -- -- Closed $31.0 million private placement financing, extending cash runway into 1Q 2025 --

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Based on the average brokerage recommendation (ABR), Kala Pharma (KALA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric.

Wall Street Analysts Think Kala Pharma (KALA) Is a Good Investment: Is It?

Kala Pharmaceuticals (KALA) closed the most recent trading day at $11.90, making no change from the previous trading session.

Kala Pharmaceuticals (KALA) Flat As Market Sinks: What You Should Know

Elys Game Technology, Corp.

Gossamer Bio Inc

Myomo

Oric Pharmaceuticals

Soleno Therapeutics

Sitio Royalties Corp

While everyone knows that in order to have a market, there must be bulls and bears, that's not going to stop people from attempting to garner intense profits from top short-squeeze candidates. To quickly summarize, shorting stocks involves borrowing shares to initiate the “negative” position.

7 Top Short-Squeeze Candidates to Watch in February

FDA Accepted IND Filing for the company to initiate a phase 2b study using KPI-012 for the treatment of patients with the persistent corneal epithelial defect. The phase 2b study, using KPI-012 for the treatment of patients with a persistent corneal epithelial defect, is expected to begin in Q1 of 2023.

Kala Pharma: Rare Eye Disease Biotech Lottery Ticket Based On Stem Cell Platform

Anheuser-Busch InBev

Rayonier Advanced Materials

RYAM, BUD and KALA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 17, 2022.

Best Momentum Stocks to Buy for January 17th

Kala pharmaceuticals underwent a massive rally over the past few days, and by all indications, the stock price is now headed toward a bottom.

Kala Pharmaceuticals Up 400% In The Past Month, What's Next?

Shares of Kala Pharmaceuticals Inc. KALA, +39.53% have rocketed higher in for three-straight sessions, toward a more-than 8-fold gain, since the biopharmaceutical company announced positive news regarding its treatment of persistent corneal epithelial defect (PCED). The stock exploded up 218.4% on Wednesday, after the Food and Drug Administration accepted the investigational new drug (IND) application for the PCED treatment, KPI-012, then rose 99.0% on Thursday.

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

The mean of analysts' price targets for Kala Pharma (KALA) points to a 267.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 268% Upside in Kala Pharma (KALA): Here's What You Should Know

Kala Pharmaceuticals Inc KALA shares are trading higher Thursday. The stock appears to be moving on continued momentum after the company on Wednesday announced FDA acceptance of an investigational new drug (IND) application for KPI-012 for the treatment of persistent corneal epithelial defect.

Kala Pharmaceuticals Stock Continues To Soar: What's Going On? - Kala Pharmaceuticals (NASDAQ:KALA)

Kala Pharmaceuticals Inc (NASDAQ:KALA) is bucking the broader-market trend this afternoon, up 283.2% lead to trade at $15.02.

Kala Pharmaceuticals Stock Surges on FDA Update

Amid another soft performance for the benchmark equities index, rare-eye disease specialist Kala Pharmaceuticals (NASDAQ: KALA ) lit up the overcast sky with a stunning triple-digit performance. Yesterday afternoon, the company announced that it received approval by the Food and Drug Administration (FDA) for its investigational new drug (IND) application centered on its flagship therapeutic candidate KPI-012.

Why Is Kala Pharmaceuticals (KALA) Stock Soaring 240%?

The FDA accepts Kala Pharmaceuticals' (KALA) investigational new drug application for pipeline candidate KPI-012 for treating persistent corneal epithelial defect. Stock up.

Kala Pharmaceuticals (KALA) Up as FDA Accepts IND for KPI-012

Shares of Kala Pharmaceuticals Inc. KALA, +1.03% shot up 45.7% in premarket trading Wednesday, after the biopharmaceutical company said the Food and Drug Administration accepted its investigational new drug (IND) application for KPI-012, its treatment of persistent corneal epithelial defect (PCED). With the acceptance, the company said late Tuesday that it is now turning its focus to clinical execution, and is looking to initiate a Phase 2 trial KPI-012 in the first quarter of 2023.

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

-- On-track to initiate Phase 2b trial in 1Q 2023; Topline data expected in 1Q 2024 --  -- Received remaining $25 million investment under previously announced private placement financing -- ARLINGTON, Mass., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that the U.S. Food and Drug Administration (FDA) has accepted an investigational new drug (IND) application for the company's lead product candidate, KPI-012, a human mesenchymal stem cell secretome (MSC-S), initially in development for the treatment of persistent corneal epithelial defect (PCED).

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Kala Pharma (KALA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why Kala Pharma (KALA) Looks Ripe for Bottom Fishing

-- On-track to initiate Phase 2b trial in 4Q 2022, with topline data expected in 1Q 2024 -- -- Cash runway extended into 1Q 2025, pending receipt of second tranche from previously announced financing, due upon FDA acceptance of KPI-012 IND -- ARLINGTON, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for KPI-012 for the treatment of Persistent Corneal Epithelial Defect (PCED). Subject to acceptance of the IND by the FDA, Kala remains on-track to initiate a Phase 2b clinical trial of KPI-012 for PCED in the fourth quarter of 2022. Topline safety and efficacy data from the trial is expected in the first quarter of 2024. If positive, this trial could serve as the first of two pivotal trials needed to support the submission of a Biologics License Agreement (BLA) to the FDA. Following acceptance of the IND for KPI-012 by the FDA, Kala will receive the second tranche from the private placement of securities announced earlier today which, together with current cash on hand, Kala expects will extend its projected cash runway into the first quarter of 2025.

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

ARLINGTON, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it has entered into a definitive agreement with a life sciences-focused investor for the sale, in a private placement priced at-the-market under Nasdaq rules, of shares of its common stock and Series E Convertible Non-Redeemable Preferred Stock (Series E Preferred) in two tranches for gross proceeds of up to $31 million.

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

-- Planning to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 -- -- Ended Quarter with $52.4 million in Cash; Sufficient for Funding Operations into 2Q 2024 -- ARLINGTON, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

ARLINGTON, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ: KALA) (“Kala” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced the appointment of Marjan Farid, M.D., to its Board of Directors. Dr. Farid, who is currently Professor of Clinical Ophthalmology, Director of Cornea, Refractive & Cataract Surgery, and Vice Chair of Ophthalmic Faculty at the Gavin Herbert Eye Institute, University of California Irvine (UCI), founded the Severe Ocular Surface Disease Center at UCI and is an industry leader in the care and treatment of corneal diseases.

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

Common Stock Will Begin Trading on Split-Adjusted Basis on October 21, 2022 Common Stock Will Begin Trading on Split-Adjusted Basis on October 21, 2022

Kala Pharmaceuticals Announces Reverse Stock Split

ARLINGTON, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it will present at the H.C. Wainwright 24th Annual Global Investment Conference, being held virtually and in New York, NY. A pre-recorded fireside chat will be made available beginning Monday, September 12, 2022 at 7:00 a.m. ET. Management will also be available for one-on-one meetings throughout the conference.

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

ARLINGTON, Mass., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as an inducement award outside the Company's 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

News for Kala Pharmaceuticals Stock (KALA)